Home Journals Subjects About My LA Reviewers Authors News Submit
Username: Password:
.
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


Enter the three character code
Visual CAPTCHA
Privacy Statement
 
 
 

Biomarkers in Cancer

Synopsis: An open access, peer reviewed electronic journal that covers all aspects of cancer and biomarkers.


Indexing: Pubmed indexing for NIH-funded research.

Processing time: Decision in 2 weeks for 90% of papers.



Latest news:

Thousands of article downloads per month. 

Click for the latest open access visibility statistics.

View factor:
Journal: 7259
Most read article: 970
Editor in chief:
Dr Barbara Guinn
ISSN: 1179-299X


 
 
 



Editor in Chief: Dr Barbara Guinn

Dr. Barbara A. Guinn is a Senior Research Fellow at The University of Southampton and a visiting scientist at King’s College London. Dr. Guinn gained her B.Sc. in Genetics from the University of Wales, Aberystwyth in 1991 and a Ph.D. in Medicine from the University of Wales College of Medicine, Cardiff in 1995. Dr. Guinn was one of the first Leukaemia Research Fund Gordon Piller Ph.D. students in the year this prestigious award was initiated. Dr. Guinn undertook two postdoctoral fellowships at the University of Toronto (Autologous Bone Marrow Transplant Unit, Toronto General Hospital and Department of Immunology) and has maintained a history of support from the Leukaemia Research Fund throughout her career. In addition, Dr Guinn has received funding from Cancer Research U.K., the Elimination of Leukaemia Fund, Wessex Cancer Trust and British Society for Haematology. Dr. Guinn has published over 50 peer-reviewed manuscripts. She is on the editorial board of five journals and reviews manuscripts for more than 30 scientific journals on an ad hoc basis.

Dr. Guinn’s research at King’s College London, and more recently at the University of Southampton, has focused on the identification of leukaemia antigens in acute myeloid leukaemia using SEREX, microarray and RT-PCR. A number of epitopes from these antigens have been inserted into DNA vaccines and tested for suitability for near-future clinical trials. Dr. Guinn’s group has also worked on whole cell vaccines for acute myeloid leukaemia and B-cell lymphoma, and the development of tetramer arrays as a clinical end-point assay.

Read an interview with the Editor in Chief here.

>> Dr Guinn's latest call for papers